| Market Cap | 18.82M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -18.24M | Forward P/E | -1.06 | EPS next Y | - | 50D Avg Chg | -2.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | 0.46 | EPS next 5Y | - | 52W High Chg | -35.00% |
| Recommedations | - | Quick Ratio | 9.14 | Shares Outstanding | 53.01M | 52W Low Chg | 25.00% |
| Insider Own | 7.94% | ROA | -19.13% | Shares Float | 50.85M | Beta | 0.18 |
| Inst Own | - | ROE | -52.73% | Shares Shorted/Prior | -/- | Price | 0.35 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 4,685 | Target Price | 6.76 |
| Oper. Margin | - | Earnings Date | - | Volume | 2,835 | Change | 2.07% |
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.